A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Atul Khandekar
Advertisement
Atul Khandekar is COO of SymphonyTech Biologics
Articles by Atul Khandekar
Advertisement
Latest Updated Articles
- A Systematic Evaluation of Risks and Mitigation Strategies for Convalescent Plasma Therapy for COVID-19
Published: February 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
2
Establishing Risk Assessments for AI in Bio-Manufacturing
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
5
